secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHINA PHARMA HOLDINGS, INC. (CPHI)
CIK:        0001106644
Form:       8-K
Filed at:   2024-12-26T23:59:59+00:00
Accession:  0001213900-24-112658
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

China Pharma shareholders approve reverse stock split at 1:10–1:20; all directors elected
--------------------------------------------------------------------------------

- All five director nominees elected: Zhilin Li, Heung Mei Tsui (non-independent), Gene Michael Bennett, Yingwen Zhang, Baowen Dong (independent).
- Amendment to allow reverse stock split at ratio between 1:10 and 1:20 approved; board retains discretion to effect.
- Amendment No.2 to the 2010 Long-Term Incentive Plan approved by shareholders.
- Advisory vote on executive compensation approved; frequency set at every three years.
- Annual meeting held Dec 22, 2024; quorum of ~52% (9,688,133 shares) of outstanding stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1106644/000121390024112658/0001213900-24-112658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1106644/000121390024112658/ea022580301-8k_chinapharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-112658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer